Zachary Bessette

GU Oncology Now

Moffitt Cancer Center researchers have developed the first patient-reported outcome (PRO) measure for patients receiving radionuclide therapy (RNT) to guide treatment and improve quality of care.Lisa M. Gudenkauf, PhD, and colleagues published their findings in <a href="https://jnm.snmjournals.org/content/early/2023/01/12/jnumed.122.264946" target="_blank" rel="noopener">The Journal of Nuclear Medicine</a>.While the field of RNT for prostate cancer is growing steadily, current PRO measures are mostly designed to assess impacts of chemotherapy or surgery.To develop the new PRO tool, researchers first identified relevant symptoms and toxicities by reviewing published trials and interviews with patients with prostate cancer receiving RNT (n=29), their caregivers (n=14), and their clinicians (n=11). Items were selected for measure inclusion and further refined after input from RNT experts.The final PRO questionnaire, called the Functional Assessment of Cancer Therapy &ndash; Radionuclide Therapy (FACT-RNT), was created with patient input. It includes 15 questions on symptoms and side effects such as dry mouth, nausea, loss of appetite, bone pain, fatigue, and feelings of isolation due to illness or treatment.&ldquo;We were thorough in determining which symptoms and side effects are important to patients receiving RNT for prostate cancer,&rdquo; said Dr. Gudenkauf in a <a href="https://www.eurekalert.org/news-releases/977140" target="_blank" rel="noopener">press release</a>.&ldquo;The FACT-RNT will help future researchers better understand the impact of RNT and other therapies on quality of life in patients with prostate cancer,&rdquo; added Brian Gonzalez, PhD, senior study author and associate member of the Department of Health Outcomes and Behavior at Moffitt Cancer Center.The US Department of Defense and the National Cancer Institute supported this study.

Novel PRO Tool for Patients With Prostate Cancer After Radionuclide Therapy

Radioligand therapy prostate-specific membrane antigen

Moffitt Cancer Center researchers have developed the first PRO measure for patients receiving radionuclide therapy to guide treatment and improve QoC.

Novel PRO Tool for Prostate Cancer Patients After RNT

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe